Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lysiane Mousset"'
Autor:
Jean-François Rossi, Emmanuel Bonnet, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, Roland Sicard, Jean-Pierre Daures, Marion Bonifacy, Lysiane Mousset, Christel Castelli, Emmanuel Goffart
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 44, Iss , Pp S19-S20 (2022)
Pts with HM may have low or delayed specific immune response after usual vaccination due to immune deficiency, associated to the disease or to the therapy. In this real-life study, 235 pts vaccinated with BNTCV (BioNTech Pfizer) were monitored for 2
Externí odkaz:
https://doaj.org/article/a48e19eeb6004cc2a3a73c51a20f201b
Autor:
Jean-François Rossi, Emmanuel Bonnet, Christel Castelli, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, Roland Sicard, Jean-Pierre Daures, Marion Bonifacy, Lysiane Mousset, Emmanuel Goffart
Publikováno v:
Vaccines, Vol 11, Iss 3, p 493 (2023)
Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 yea
Externí odkaz:
https://doaj.org/article/acdc3b2d70d9464b81b7f31cf3308e1d
Autor:
Jean-François Rossi, Emmanuel Bonnet, Christel Castelli, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, Roland Sicard, Jean-Pierre Daures, Marion Bonifacy, Lysiane Mousset, Emmanuel Goffart
Hematological malignancies patients (HM) have heterogeneous serological response after vaccination. Real-world data. 216 patients with HM and 12 non-malignant hemopathies received BNT162b2 COVID-19 and monitored for >1 year. The first 43 patients had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf05a7b0f69392c91129ac4ae58016ec
https://doi.org/10.21203/rs.3.rs-2190058/v1
https://doi.org/10.21203/rs.3.rs-2190058/v1
Autor:
Celeste David, Jerome Dinet, Rania Boustany, Sophie Heraud, Roland Sicard, Emma Wisniewski, Jean-François Rossi, Marion Velensek, Marion Bonifacy, Emmanuel Bonnet, Emmanuel Goffard, Jean Pierre Daures, Lysiane Mousset
Publikováno v:
Blood
Pts with HM and particularly those under therapy or with secondary immune deficiency have been reported to have a low or delayed specific immune response. In addition, pts receiving rituximab for either HM or auto-immune disease presented a low speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74fad863ffa808a1eb3ce380e8b3d3eb
http://europepmc.org/articles/PMC8701686
http://europepmc.org/articles/PMC8701686